Retatrutide Protocol: Weekly GLP-1/GIP/GCG Dosing

Retatrutide: The Triple-Axis GLP-1/GIP/GCG Agonist

Retatrutide represents a meaningful advance in metabolic peptide therapy—a single-injection weekly agent that activates three distinct incretin receptors simultaneously: GLP-1R, GIP-R, and GCG-R. Understanding the pharmacokinetics and dosing schedule is essential before self-administering.

Why Sunday Injections Make Sense

Weekly GLP-1 receptor agonists achieve steady-state concentrations around day 4-5 post-injection. A fixed day (Sunday) creates a predictable rhythm that:

Synchronizes with your circadian cortisol nadir, typically 2-4 hours post-waking. Injecting when endogenous cortisol is declining may reduce inflammatory response to the subcutaneous bolus.
Aligns appetite suppression with weekly meal planning. GLP-1 effects peak 24-48 hours post-injection, coinciding with Monday-Tuesday eating behavior.
Enables consistent lab draw timing. If you're monitoring IGF-1, fasting glucose, or lipid panels, drawing labs exactly 7 days post-injection standardizes your data.
Reduces medication non-adherence. A single weekly ritual beats remembering daily or twice-daily dosing.

Mechanism: Triple-Receptor Activation

Retatrutide's structure activates:

GLP-1 Receptor: Slows gastric emptying, increases satiety signaling to the hypothalamus via vagal afferents, enhances insulin secretion when glucose is elevated (glucose-dependent), suppresses glucagon inappropriately in hypoglycemia (risk mitigation required).

GIP Receptor: Potentiates glucose-dependent insulin secretion synergistically with GLP-1. GIP was historically dismissed as an "incretin hormone" but reactivation improves both weight loss and carbohydrate tolerance. Dual GLP-1/GIP agonists (tirzepatide) demonstrated superior weight loss vs GLP-1-only agents in SUMO trials.

GCG Receptor: Full glucagon agonism increases hepatic glucose output and energy expenditure. This is not alpha-cell glucagon activation (which causes hyperglycemia in non-diabetics); it's pharmacological GCG-R stimulation that upregulates brown adipose tissue thermogenesis and increases lipolysis. Retatrutide is the first approved compound adding GCG-R agonism to the dual GLP-1/GIP backbone.

Pharmacokinetics & Steady-State Dosing

Retatrutide has a half-life of 6-7 days. Peak serum concentration occurs at 24-48 hours post-injection. Weekly dosing achieves ~80% accumulation by week 4; steady-state is reached by week 8-12.

Starting protocols typically begin at 0.5 mg weekly, titrating upward by 0.5 mg increments every 2-4 weeks to a target of 2.5-5 mg depending on tolerability and clinical response. Some providers extend to 10 mg weekly off-label in obesity trials.

Injecting on the same day each week (Sunday) creates predictable pharmacokinetics. If you deviate—say, injecting Monday or Saturday—you'll flatten the concentration curve and lose the therapeutic peak.

Pre-Injection Baseline Labs

Before your first Sunday injection, order:

Fasting glucose & HbA1c: Establish baseline glycemic control. Retatrutide-induced nausea can worsen glycemic variability if insulin isn't adjusted.
Lipid panel (TC, LDL, HDL, triglycerides): GLP-1/GIP agonists improve triglycerides >20% in many subjects; LDL may rise (often particle size shift, not atherogenic).
Liver function tests (AST, ALT, GGT, bilirubin): Retatrutide undergoes hepatic metabolism. Baseline cirrhosis or steatosis must be ruled out.
Thyroid panel (TSH, free T4): GLP-1 agonists accelerate gastric transit; nutrient absorption declines. Hypothyroidism risk is modest but non-zero.
Calcitonin: GLP-1/GCG-R agonists stimulate calcitonin release from parafollicular cells. If calcitonin is elevated at baseline (>15 pg/mL), medullary thyroid carcinoma (MTC) is contraindicated.
Creatinine & eGFR: Dehydration from nausea can transiently reduce GFR. Know your baseline.
Lipase: Pancreatitis is rare but documented. Establish baseline.

Synergistic Supplement Stack

Magnesium glycinate, 300-400 mg daily: GLP-1 agonists increase insulin secretion. Hyperinsulinemia depletes intracellular magnesium. Glycinate form avoids osmotic diarrhea (common with magnesium citrate on these agents). Take evening dose, separate from food.

Zinc picolinate, 15-25 mg daily: Retatrutide accelerates gastric emptying, reducing zinc absorption from food. Picolinate form has the highest bioavailability. Take in morning with food.

Vitamin D3 + K2 (MK-7): 4,000-5,000 IU D3 + 180 mcg K2 daily. GLP-1-induced weight loss mobilizes fat-stored vitamin D; inadequate K2 blunts osteocalcin activation. Synergizes with creatine to preserve lean mass.

Creatine monohydrate, 5 g daily: Retatrutide suppresses appetite; protein intake often drops below 1.2 g/kg lean mass. Creatine buffers ATP availability in skeletal muscle, reducing catabolism. Increases intramuscular water; ensure hydration.

Omega-3 (EPA/DHA), 2-3 g daily: Retatrutide improves lipid particle size, but omega-3 further reduces triglyceride VLDL and protects endothelial function against transient hyperlipidemia spikes.

NAC (N-acetyl cysteine), 600-1,200 mg daily: Supports glutathione synthesis; GLP-1 agonists increase metabolic flux and ROS production during thermogenesis. NAC mitigates oxidative stress.

Methylated B-complex: Retatrutide accelerates carbohydrate oxidation. B1 (thiamine), B6 (P5P), and B12 (methylcobalamin) are cofactors in glycolytic enzymes. Methylated forms bypass genetic polymorphisms in MTHFR and other enzymes.

Post-Injection Monitoring

Week 4, 8, 12: Repeat glucose, lipids, liver function. If on concurrent thyroid medication, recheck TSH.

Week 12 onwards: If stable, labs quarterly. Watch for:

Hypoglycemia events (rare on monotherapy; serious if combined with insulin/sulfonylureas).
GI adverse events (nausea, constipation, vomiting). Typically peak week 1-3 of dose escalation, then resolve.
Pancreatitis symptoms (epigastric pain, lipase >3x ULN). Discontinue immediately.
Thyroid antibodies (if TSH drifts upward; monitor annually).

Bottom Line

Retatrutide's weekly Sunday injection schedule is pharmacologically sound—it synchronizes with circadian biology, simplifies adherence, and allows standardized lab monitoring. The triple GLP-1/GIP/GCG mechanism is more potent than dual agonists for thermogenesis and lean-mass preservation. Success depends on baseline labs (especially calcitonin and liver function), appropriate supplement stacking (magnesium, zinc, creatine, NAC, methylated B vitamins), and consistent weekly dosing. Work with a provider experienced in peptide therapy; do not self-titrate beyond established protocols.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.